Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 14/20 | 0.81 |
| ▸ | F10 | P00742 | 2/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.64 |
| ▸ | PRKCG | P05129 | 2/20 | 0.64 |
| ▸ | CDK1 | P06493 | 2/20 | 0.64 |
| ▸ | PIM1 | P11309 | 2/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | AKT1 | P31749 | 2/20 | 0.64 |
| ▸ | AKT2 | P31751 | 2/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | NEK2 | P51955 | 2/20 | 0.64 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semapimod SCHEMBL18758868 | 0.97 | FURIN (0.85) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL435405 | 0.97 | FURIN (0.85) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL29624033 | 0.96 | FURIN (0.83) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL12201344 | 0.77 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| SCHEMBL11989635 | 0.77 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| SCHEMBL16445937 | 0.77 | FURIN (0.55) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL6150586 | 0.77 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| SCHEMBL6149232 | 0.77 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 | |
| SCHEMBL8445590 | 0.77 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 | |
| SCHEMBL5442050 | 0.77 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| EP-4674954-A1 | TUMOR INFILTRATING LYMPHOCYTE EXPRESSING MEMBRANE-BOUND CYTOKINE | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| CN-119192383-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-112218656-B | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | BioAlta, LLC | 2024-10-17 | — | — | US | disclosed |
| US-20240336701-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2024-10-10 | — | — | US | disclosed |
| US-20240325538-A1 | TUMOR INFILTRATION LYMPHOCYTE CULTURE MEDIUM AND APPLICATION THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024179465-A1 | TUMOR INFILTRATING LYMPHOCYTE EXPRESSING MEMBRANE-BOUND CYTOKINE | 上海君赛生物科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| WO-2015090230-A1 | HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20140322275-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2014-10-30 | — | — | US | disclosed |
| WO-2014163714-A2 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014160160-A2 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014150937-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153270-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014130657-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-28 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050203072-A1 | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | FURIN 2371/4885F10 2759/4885CHEK1 1285/4885 |
| US-20050203072-A1 | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | MAP3K1, MAP3K5, MAP3K11 | FURIN 2511/4885F10 4379/4885CHEK1 1431/4885 |
| US-20240336701-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | ENTPD2, ENTPD1, ENTPD3 | FURIN 647/4885F10 1955/4885CHEK1 3674/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | FURIN 1339/4885F10 4519/4885CHEK1 594/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | FURIN 3822/4885F10 4470/4885CHEK1 352/4885 |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | CD274, PDCD1LG2, PDCD1 | FURIN 1841/4885F10 2726/4885CHEK1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.